Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
about
Thrombosis Associated with Viral HepatitisEltrombopag in chronic hepatitis CThe Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current EvidenceThrombocytopenia and infections.Changing common sense: Anti-platelet/coagulation therapy against cirrhosis.Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.Hepatitis C among Egyptian Patients Referred for Bone Marrow Examination: Seroprevalence and Analysis of Hematological Findings.Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I studyManagement of thrombocytopenia in advanced liver diseaseEltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.Hospital-acquired thrombocytopenia.Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Economic assessment of eltrombopag in the treatment of thrombocytopenia.Eltrombopag for treatment of thrombocytopenia-associated disorders.Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.Severe Thrombotic Complication of Eltrombopag in a Cirrhotic Patient.Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.Alternatives to allogeneic platelet transfusion.Thrombocytopenia in chronic liver disease.Thrombocytopenia in Patients with Chronic Hepatitis C Virus InfectionThrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.Virus-related liver cirrhosis: molecular basis and therapeutic options.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaEltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
P2860
Q26781784-436C0BF0-8FFD-4D28-ADCD-857DCFD1DEABQ26849334-56F90A96-3F41-4BFF-8022-D8AF956C4BEBQ28074484-A25D6A20-33F9-4E55-84A3-71F8D74BE524Q30240119-0BA4E76B-DBF0-48C9-B61A-23664D7DEBA8Q30379953-E2503024-7B97-4542-AE46-D52CFC772870Q33414605-1F73872F-C637-4C8D-B6C7-27282B3CDD7EQ33415225-0170A2A4-8796-4A3E-BE76-AED6C8B02835Q33417307-5065AD26-BB2F-40EF-B372-D7885392654EQ33417372-C90D470C-8C3F-4122-9882-2BAEC3BA4616Q33417667-DC885A2C-5204-42DE-A9FB-174E90A0D785Q33418303-58F6890A-BC77-4652-AACA-DAC73D1FD7A0Q33419312-BE68BE7A-96F0-4852-A2D8-B7CB113582F0Q33419462-EA38EBB7-63FD-4E27-B191-22426CE436CFQ33420280-24DD5B44-0F95-408D-A0F4-68DB164CD041Q33421239-1751BBB1-4C16-490F-ABFF-C1D33ABFCF62Q33423922-643079FC-1B60-4CE7-A533-2C9851B1D66FQ33424436-A2B734B3-4A66-40A6-9F06-3783A03B0D46Q33425805-31705BE2-7E1E-467C-BDEB-F1C828226991Q33426112-7E456123-CD3C-4158-85E4-92A61B046301Q33427048-8A151E7F-DC1C-481D-8AF4-6FA9FF4B62A2Q33430592-25885F29-5C22-4986-AC3C-07CC40B421EFQ33430951-7DD66F78-891C-48DA-A888-1BE465293A98Q33435484-58123938-5B95-4345-83AD-2B7248565FA4Q33436905-2D90A655-FD48-4639-B849-2379DE12249EQ33440130-3EDC56F2-FD55-4ECA-BE47-F5E68D56590EQ33440149-2B66BF7B-5C25-495F-AD6A-83C428A8FC01Q33441627-F19D0BD6-3C26-4EE5-BFF8-3B56B9B65585Q33576531-B8C2AE22-1585-49A4-AF94-1A070B19113DQ33718267-DCE4F9A3-EEB9-45E0-BE9B-0142499CCAA3Q36460249-14ACE7B3-BBA8-4B3E-B61C-A67C0086A43AQ50231149-4324BFE2-E412-44B5-A068-BE26AEA2DD1B
P2860
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Eltrombopag increases platelet ...... r effective antiviral therapy.
@ast
Eltrombopag increases platelet ...... r effective antiviral therapy.
@en
type
label
Eltrombopag increases platelet ...... r effective antiviral therapy.
@ast
Eltrombopag increases platelet ...... r effective antiviral therapy.
@en
prefLabel
Eltrombopag increases platelet ...... r effective antiviral therapy.
@ast
Eltrombopag increases platelet ...... r effective antiviral therapy.
@en
P2093
P50
P1433
P1476
Eltrombopag increases platelet ...... r effective antiviral therapy.
@en
P2093
Aftab Mohsin
Andres Brainsky
Dickens Theodore
Eric Lawitz
Fiona M Campbell
Geoffrey M Dusheiko
Ghias-Un-Nabi Tayyab
Igor Bakulin
James Geib
Kwang-Hyub Han
P304
P356
10.1053/J.GASTRO.2013.10.012
P407
P577
2013-10-12T00:00:00Z